U.S. Patent Nos.
7,332,289 (Method of Purifying Protein) 7,521,052 (Methods for Treating Interleukin-6 Related Diseases) 8,398,980 (Subtypes of Humanized Antibody Against Interleuken-6 Receptor) 8,512,983 (Production of Proteins in Glutamine-Free Cell Culture Media) 8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 8,734,800 (Subtypes of Humanized Antibody Against Interleukin-6 Receptor) 9,714,293 (Production of Proteins in Glutamine-Free Cell Culture Media) 9,902,777 (Methods for Producing Subtypes of Humanized Antibody Against Interleukin-6 Receptor) 10,017,732 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,336,983 (Method for Increasing the Specific Production Rate of Eukaryotic Cells) 10,501,769 (Method for the Production of a Glycosylated Immunoglobulin) 10,662,237 (Method to Improve Virus Filtration Capacity) 10,676,710 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,744,201 (Method for Treating Rheumatoid Arthritis with a Human IL-6 Receptor Antibody and Methotrexate) 10,829,732 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,982,003 (Production of Proteins in Glutamine-Free Cell Culture Media) 11,021,728 (Method for the Production of a Glycosylated Immunoglobulin) 11,078,294 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 11,136,610 (Method for the Production of a Glycosylated Immunoglobulin) 11,377,678 (Method for the Production of a Glycosylated Immunoglobulin)
Plaintiffs
Genentech, Inc.; Chugai Pharmaceutical Co., Ltd.; Hoffmann-La Roche Inc.
Defendants
Biogen MA Inc.; Bio-Thera Solutions, Ltd.
Status
Stipulated Dismissal Due to Settlement
BPCIA
Y